Pfizer Cites Tariff Uncertainty as Barrier to U.S. Investment
Pfizer CEO Albert Bourla highlighted trade policy uncertainties as a significant constraint on domestic investment during the company’s Q1 earnings call. The pharmaceutical giant seeks clarity on potential tariffs for imported drugs before committing to new U.S.-based R&D and manufacturing projects.
"In periods of uncertainty, everybody is controlling their cost," Bourla stated, emphasizing how trade policy volatility forces corporate caution. The Trump administration’s proposed tariffs aim to reshore pharmaceutical production, but industry leaders demand predictable policy frameworks to justify capital expenditures.